We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Kuros Biosciences AG (KURN) CHF0.1

Sell:7.21 CHF Buy:7.25 CHF Change: 0.91 CHF (11.21%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.21 CHF
Buy:7.25 CHF
Change: 0.91 CHF (11.21%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.21 CHF
Buy:7.25 CHF
Change: 0.91 CHF (11.21%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

Contact details

Wagistrasse 25
+41 (44) 7334747

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
299.35 million CHF
Shares in issue:
36.85 million
SIX Swiss Exchange
Swiss Franc
Swiss All Share Index

Key personnel

  • Chris Fair
    Chief Executive Officer, Member of the Executive Board
  • Daniel Geiger
    Chief Financial Officer, Member of the Executive Board
  • Sjoerd Musters
    Chief Operating Officer, Member of the Executive Board
  • Joost de Bruijn
    Executive Director, Member of the Executive Board, President of Innovation and Strategy

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.